Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$29.68
-0.74 (-2.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $173.9M · quality 76.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.6B
P/E
13.4x
↓EV/EBITDA
10.0x
↓ROE
13.5%
↑Gross Margin
58.4%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.5%
FCF CAGR
+5.5%
FCF margin
5.2%
FCF / Net income
0.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.37B · net income $359.8M · FCF $173.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.37B | $3.37B | $3.50B | $4.21B | $3.64B |
| Net Income | $359.8M | $359.8M | $362.2M | $521.5M | $408.1M |
| EBITDA | $450.6M | $450.6M | $446.7M | $615.1M | $481.6M |
| EPS | 2.37 | 2.37 | 2.38 | 3.41 | 2.68 |
| Gross Margin | 58.4% | 58.4% | 47.7% | 46.0% | 43.3% |
| Operating Margin | 8.4% | 8.4% | 5.7% | 8.6% | 9.1% |
| Net Margin | 10.7% | 10.7% | 10.3% | 12.4% | 11.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.07 | 0.05 | 0.03 |
| Current Ratio | 1.55 | 1.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $173.9M | $173.9M | $114.0M | $203.9M | $147.9M |
| Returns | |||||
| ROE | 13.5% | 13.5% | 14.9% | 23.2% | 21.9% |
| Valuation | |||||
| P/E | 13.37 | 13.37 | 17.31 | 19.28 | 19.70 |
| EV/EBITDA | 10.03 | 10.03 | 14.06 | 16.04 | 16.35 |
| P/B | 1.70 | 1.70 | 2.57 | 4.47 | 4.32 |
| Growth & Yield | |||||
| Revenue Growth | -3.9% | -3.9% | -16.8% | 15.7% | — |
| EPS Growth | -0.4% | -0.4% | -30.2% | 27.2% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
3.6%
EPS terminal req.
$2.63
Spread vs growth
-4.0%
5Y implied EPS CAGR
6.1%
EPS terminal req.
$3.19
Spread vs growth
-6.5%
10Y implied EPS CAGR
8.0%
EPS terminal req.
$5.13
Spread vs growth
-8.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.2%
Start / end P/E
16.9x → 12.5x
EPS bridge
2.38 → 2.37
Residual
+0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.